About ApoImmune


Investor Relations

ApoImmune, Inc. is a biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the host immune system to fight disease. We are building both drug discovery and clinical development capabilities that can support various research and development projects. Currently, we are concentrating our clinical capabilities on cancer as we start our first Phase I clinical trial. Our other research programs include infectious diseases, Type 1 diabetes, and cell/organ transplantation.



To receive investor information, please contact:

    Steven Downey
    President and CEO
    ApoImmune, Inc.
    1044 East Chestnut Street
    Louisville, KY 40204
    T: 502-212-2493
    sdowney[at]apoimmune.com



Home | About ApoImmune | Technologies | Careers | Contact Us | Site Map

Copyright © 2008 ApoImmune, Inc. All rights reserved.
1044 East Chestnut Street | Louisville, KY 40204 | 502-212-2493 | info@apoimmune.com